Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31719497 | 1.00 | PDE5A (0.51) | PDE5ACASP1CA1CA2VCAM1 | |
| SCHEMBL5427052 | 0.79 | PDE5A (0.36) | PDE5ACASP1ALDH1A1 | |
| SCHEMBL31266461 | 0.75 | MAOB (0.49) | PDE5AMAOBALDH1A1LMNANPSR1 | |
| SCHEMBL13074276 | 0.74 | CA2 (0.43) | CA1CA2CHUKALDH1A1 | |
| SCHEMBL31719573 | 0.74 | PDE5A (0.61) | PDE5A | |
| SCHEMBL7985449 | 0.74 | PDE5A (0.65) | PDE5A | |
| SCHEMBL20116697 | 0.71 | ALDH1A1 (0.43) | PDE5ACA1CA2CHUKALDH1A1 | |
| SCHEMBL30506249 | 0.71 | ALDH1A1 (0.43) | PDE5ACA1CA2CHUKALDH1A1 | |
| SCHEMBL31146783 | 0.70 | PDE5A (0.42) | PDE5AALDH1A1LMNAMAPT | |
| SCHEMBL3601771 | 0.70 | PDE5A (0.42) | PDE5AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140824-A1 | PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-07-04 | — | — | WO | disclosed |
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2170866-B1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153633-B2 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2009002469-A1 | PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| CN-1210265-C | Phthalazine derivatives and remedies for erectile dysfunction | EISAI CO LTD (JP) | 2005-07-13 | — | — | CN | disclosed |
| US-6699870-B2 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. | 2003-06-05 | — | — | US | disclosed |
| US-6498159-B1 | SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE | EISAI CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| US-6288064-B1 | PHOSPHODIESTERASE INHIBITORS; PHTHALAZINE DERIVATIVES | EISAI CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| US-6218392-B1 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, MYOCARDIAL INFARCT AND CHRONIC AND ACUTE CARDIAC FAILURE, PULMONARY HYPERTENSION, ARTERIOSCLEROSIS AND BRONCHIAL ASTHMA | EISAI CO., LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| CN-1275124-A | Phthalazine derivatives and remedies for erectile dysfunction | EISAI CO LTD (JP) | 2000-11-29 | — | — | CN | disclosed |
| EP-0920868-A1 | REMEDY FOR ERECTION FAILURE COMPRISING FUSED PYRIDAZINE COMPOUND | Eisai Co., Ltd. (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-5849741-A | Fused pyridazine compounds | EISAI CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0722936-A1 | FUSED PYRIDAZINE COMPOUND | Eisai Co., Ltd. (JP) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048259-A1 | Phthalazine compounds, compositions and methods of use | VHL, HDAC5, SUZ12 | PDE5A 1148/4885CASP1 1415/4885CA1 938/4885 |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | CLIC1, CBR1, CBR3 | PDE5A 4/4885CASP1 719/4885CA1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.